We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
CRISPR Therapeutics AG | NASDAQ:CRSP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.47 | -2.58% | 55.59 | 55.16 | 55.60 | 57.10 | 55.27 | 57.01 | 1,377,182 | 01:00:00 |
FORM 4
[
X
]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person
*
CELGENE CORP /DE/ |
2. Issuer Name
and
Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __ X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
86 MORRIS AVENUE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
SUMMIT, NJ 07901 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 11/3/2017 | S | 22759 | D | $19.10 (1) | 4812221 | I | See explanation of responses (2) (3) | ||
Common Stock | 11/6/2017 | S | 79327 | D | $18.89 (1) | 4732894 | I | See explanation of responses (2) (3) | ||
Common Stock | 11/7/2017 | S | 23000 | D | $18.54 (1) | 4709894 | I | See explanation of responses (2) (3) | ||
Common Stock | 11/8/2017 | S | 16875 | D | $18.06 (1) | 4693019 | I | See explanation of responses (2) (3) | ||
Common Stock | 11/9/2017 | S | 20000 | D | $17.08 (1) | 4673019 | I | See explanation of responses (2) (3) | ||
Common Stock | 11/10/2017 | S | 10000 | D | $17.28 (1) | 4663019 | I | See explanation of responses (2) (3) | ||
Common Stock | 11/13/2017 | S | 65093 | D | $17.76 (1) | 4597926 | I | See explanation of responses (2) (3) | ||
Common Stock | 11/14/2017 | S | 14907 | D | $17.19 (1) | 4583019 | I | See explanation of responses (2) (3) | ||
Common Stock | 11/15/2017 | S | 15000 | D | $17.67 (1) | 4568019 | I | See explanation of responses (2) (3) | ||
Common Stock | 11/16/2017 | S | 105000 | D | $18.39 (4) | 4463019 | I | See explanation of responses (2) (3) | ||
Common Stock | 11/17/2017 | S | 51282 | D | $18.44 (4) | 4411737 | I | See explanation of responses (2) (3) | ||
Common Stock | 11/20/2017 | S | 158718 | D | $19.02 (4) | 4253019 | I | See explanation of responses (2) (3) | ||
Common Stock | 11/21/2018 | S | 80000 | D | $19.25 (4) | 4173019 | I | See explanation of responses (2) (3) | ||
Common Stock | 11/22/2017 | S | 256000 | D | $19.76 (4) | 3917019 | I | See explanation of responses (2) (3) | ||
Common Stock | 11/24/2017 | S | 26010 | D | $20.00 (4) | 3891009 | I | See explanation of responses (2) (3) | ||
Common Stock | 11/27/2017 | S | 27990 | D | $19.75 (4) | 3863019 | I | See explanation of responses (2) (3) | ||
Common Stock | 11/28/2017 | S | 5080 | D | $19.22 (4) | 3857939 | I | See explanation of responses (2) (3) | ||
Common Stock | 11/29/2017 | S | 4263 | D | $19.25 (4) | 3853676 | I | See explanation of responses (2) (3) | ||
Common Stock | 11/30/2017 | S | 12666 | D | $19.04 (4) | 3841010 | I | See explanation of responses (2) (3) | ||
Common Stock | 12/1/2017 | S | 87991 | D | $19.10 (4) | 3753019 | I | See explanation of responses (2) (3) | ||
Common Stock | 12/4/2017 | S | 30485 | D | $19.47 (4) | 3722534 | I | See explanation of responses (2) (3) |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
CELGENE CORP /DE/
86 MORRIS AVENUE SUMMIT, NJ 07901 |
|
X |
|
|
Signatures
|
||
/s/ Peter N. Kellogg, Executive Vice President and Chief Financial Officer | 12/6/2017 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year CRISPR Therapeutics Chart |
1 Month CRISPR Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions